Dendritic cell vaccination in glioblastoma after fluorescence-guided resection
Valle RD, de Cerio AL, Inoges S [ES], Tejada S [ES], Pastor F, Villanueva H, Gallego J [ES], Espinos J [ES], Aristu J [ES], Idoate MA [ES], Andreu E [ES], Bendandi M.
Department of Neurosurgery, University of Navarra Hospital, 31008 Pamplona, Navarra, Spain
Revisão:World Journal of Clínical Oncology
Data: 10/Nov/2012Neurologia [ES] Oncologia Médica Neurocirurgia Área de Terapia Celular [ES] Anatomia Patológica [ES] Medicina Nuclear [ES]
To assess whether the addition of a customized, active immunotherapy to standard of care including fluorescence-guided surgery, may provide hints of an improved survival for patients with poor-prognosis, incurable glioblastoma multiform.
Preliminary to our ongoing, phase-II clinical trial, we conducted a small pilot study enrolling five consecutive patients with resectable glioblastoma. In terms of Recursive Partitioning Analysis, four patients were class V and one was class IV. In all five cases, fluorescence-guided surgery was employed, followed by rapid steroid discontinuation. Patients were then treated with a combination of standard radio-chemotherapy with temozolomide and tumor lysate-pulsed, mature dendritic cell-based vaccinations.
Though all five patients ultimately progressed, with any further treatment left to the sole decision of the treating oncologist, active immunotherapy was very well tolerated and induced specific immune responses in all three patients for whom enough material was available for such an assessment. Median progression-free survival was 16.1 mo. Even more important, median and mean overall survival were 27 mo and 26 mo, respectively. Three patients have died with an overall survival of 9 mo, 27 mo and 27.4 mo, while the other two are still alive at 32 mo and 36 mo, the former receiving treatment with bevacizumab, while the latter has now been off therapy for 12 mo. Four of five patients were alive at two years.
Active immunotherapy with tumor lysate-pulsed, autologous dendritic cells is feasible, safe, well tolerated and biologically efficacious. A phase-II study is ongoing to possibly improve further on our very encouraging clinical results.
CITAÇÃO DO ARTIGO World J Clin Oncol. 2012 Nov 10;3(11):142-9. doi: 10.5306/wjco.v3.i11.142
A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.
Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.
Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.